Results 31 to 40 of about 1,123,126 (369)

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. [PDF]

, 2017
Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ...
Abt, Evan R, Braas, Daniel, Capri, Joseph R, Cheng, Chloe M, Czernin, Johannes, Donahue, Timothy R, Faull, Kym F, Herschman, Harvey R, Kim, Woosuk, Kornblum, Harley I, Le, Thuc M, Merkurjev, Daria, Nikanjam, Mina, Poddar, Soumya, Radu, Caius G, Ribas, Antoni, Rix, Peter, Uong, Nhu T, Wei, Liu, Whitelegge, Julian, Zaretsky, Jesse   +20 more
core   +2 more sources

Identification of novel small molecule inhibitors of ETS transcription factors

FEBS Letters, EarlyView.
ETS transcription factors play an essential role in tumourigenesis and are indispensable for sprouting angiogenesis, a hallmark of cancer, which fuels tumour expansion and dissemination. Thus, targeting ETS transcription factor function could represent an effective, multifaceted strategy to block tumour growth. The evolutionarily conserved E‐Twenty‐Six
Shaima Abdalla, Zary Forghany, Jin Ma, Johan G. Hollander, Ruta Nachane, Karoly Szuhai, Pancras C. W. Hogendoorn, Peter ten Dijke, Dipen Shah, David A. Baker   +9 more
wiley   +1 more source

Acute myeloid leukemia: current progress and future directions

Blood Cancer Journal, 2021
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
Hagop Kantarjian, Tapan Kadia, Courtney DiNardo, Naval Daver, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi   +8 more
doaj   +1 more source

Molecular methods for genomic analyses of variant PML-RARA or other RARA-related chromosomal translocations in acute promyelocytic leukemia [PDF]

, 2012
TO THE EDITOR: We read an interesting paper by Palta et al. in a recent issue of the Korean Journal of Hematology titled, "ZBTB16-RARA variant of acute promyelocytic leukemia with tuberculosis: a case report and review of literature" [1].
Kim, Min Jin, Marschalek, Rolf, Meyer, Claus, Park, Tae Sung, Yang, John Jeongseok   +4 more
core   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

Haematologica, 2012
We analyzed 636 patients with diverse myeloproliferative neoplasms or myelodysplastic/myeloproliferative neoplasms for mutations of the Casitas B-cell lymphoma gene (CBLmut) in exons 8 and 9 and performed correlations to other genetic alterations. CBLmut
Susanne Schnittger, Ulrike Bacher, Tamara Alpermann, Andreas Reiter, Madlen Ulke, Frank Dicker, Christiane Eder, Alexander Kohlmann, Vera Grossmann, Andreas Kowarsch, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +12 more
doaj   +1 more source

Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). [PDF]

, 2011
We report an allelic series of eight mutations in GATA2 underlying Emberger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute myeloid leukemia.
C Preudhomme, Colin G Steward, Daniela T Pilz, Dimitra Dafou, F-Y Tsai, Fiona C Connell, Glen Brice, Ines Martinez-Corral, M Haugas, M Khandekar, Michael A Simpson, ML Smith, NP Rodrigues, P Callier, Peter Lunt, Peter S Mortimer, Pia Ostergaard, Q Tong, R Zheng, Richard C Trembath, Russell Keenan, S Mansour, S-J Zhang, Sahar Mansour, Sarah Smithson, Shirley Hodgson, Steve Jeffery, T Pabst, Taija Makinen, Tatjana Kilo, Victoria A Murday, W-J Song, Wesley J Woollard   +32 more
core   +1 more source

Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. [PDF]

, 2020
Mutation and translocation of fibroblast growth factor receptors often lead to aberrant signaling and cancer. This work focuses on the t(8;22)(p11;q11) chromosomal translocation which creates the breakpoint cluster region (BCR) fibroblast growth factor ...
Bisom-Rapp, Ezra W, Donoghue, Daniel J, Meyer, April N, Nelson, Katelyn N, Peiris, Malalage N   +4 more
core   +2 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source